Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them

Chimeric virus-like particles (VLPs) were developed as a candidate for allergen-specific immunotherapy. In this study, hepatitis B core antigen (HBcAg) that genetically fused to Chenopodium album polcalcin (Che a 3)–derived peptide was expressed in E. coli BL21 , purified, and VLP formation was eval...

Ausführliche Beschreibung